Chronic Kidney Disease: Mineral and Bone Disorder in Children

Seminars in Nephrology

Volumn 33, Issue 2, 2013, Pages 169-179

  Wesseling Perry, Katherine ^a   Salusky, Isidro B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

CKD mineral and bone disorder; Growth; Osteodystrophy; Parathyroid hormone; Pediatrics; PTH; Vascular calcification; Vitamin D

Indexed keywords

22 OXACALCITRIOL; ALFACALCIDOL; CALCIMIMETIC AGENT; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CINACALCET; CITRATE CALCIUM; DOXERCALCIFEROL; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; PARICALCITOL; PHOSPHATE; PHOSPHATE BINDING AGENT; VITAMIN D;

ARTICLE; BLOOD VESSEL CALCIFICATION; BODY HEIGHT; BONE DISEASE; BONE MINERALIZATION; BONE STRENGTH; BONE TURNOVER; CARDIOVASCULAR DISEASE; CHILD; CHRONIC KIDNEY DISEASE; DISEASE COURSE; DRUG EFFICACY; GROWTH DISORDER; HEMODIALYSIS; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; HYPOPHOSPHATEMIA; METABOLIC DISORDER; MINERAL METABOLISM; NONHUMAN; PATHOGENESIS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; SECONDARY HYPERPARATHYROIDISM; VITAMIN METABOLISM;

BONE DEVELOPMENT; BONE DISEASES, METABOLIC; CALCIFICATION, PHYSIOLOGIC; CALCIUM; CHILD; FIBROBLAST GROWTH FACTORS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RENAL OSTEODYSTROPHY; VASCULAR CALCIFICATION; VITAMIN D;

EID: 84875278029     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2012.12.017     Document Type: Article

References (133)

1. Moe S., Drueke T., Cunningham J., Goodman W., Martin K., Olgaard K., et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2006, 69:1945-1953.
2. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009, 113:S1-S130.
3. Portale A.A., Booth B.E., Halloran B.P., Morris R.C. Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984, 73:1580-1589.
4. Levin A., Bakris G.L., Molitch M., Smulders M., Tian J., Williams L.A., et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007, 71:31-38.
5. Bacchetta J., Dubourg L., Harambat J., Ranchin B., bou-Jaoude P., Arnaud S., et al. The influence of glomerular filtration rate and age on fibroblast growth factor 23 serum levels in pediatric chronic kidney disease. J Clin Endocrinol Metab 2010, 95:1741-1748.
6. van Husen M., Fischer A.K., Lehnhardt A., Klaassen I., Moller K., Muller-Wiefel D.E., et al. Fibroblast growth factor 23 and bone metabolism in children with chronic kidney disease. Kidney Int 2010, 78:200-206.
7. Wesseling-Perry K., Pereira R.C., Tseng C.H., Elashoff R., Zaritsky J.J., Yadin O., et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012, 7:146-152.
8. Antoniucci D.M., Yamashita T., Portale A.A. Dietary phosphorus regulates serum fibroblast growth factor-23 concentrations in healthy men. J Clin Endocrinol Metab 2006, 91:3144-3149.
9. Wesseling-Perry K., Pereira R.C., Wang H., Elashoff R.M., Sahney S., Gales B., et al. Relationship between plasma FGF-23 concentration and bone mineralization in children with renal failure on peritoneal dialysis. J Clin Endocrinol Metab 2009, 94:511-517.
10. Pereira R.C., Juppner H., Azucena-Serrano C.E., Yadin O., Salusky I.B., Wesseling-Perry K. Patterns of FGF-23, DMP1, and MEPE expression in patients with chronic kidney disease. Bone 2009, 45:1161-1168.
11. Larsson T., Nisbeth U., Ljunggren O., Juppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
12. Shimada T., Hasegawa H., Yamazaki Y., Muto T., Hino R., Takeuchi Y., et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004, 19:429-435.
13. Helvig C.F., Cuerrier D., Hosfield C.M., Ireland B., Kharebov A.Z., Kim J.W., et al. Dysregulation of renal vitamin D metabolism in the uremic rat. Kidney Int 2010, 78:463-472.
14. Ben-Dov I.Z., Galitzer H., Lavi-Moshayoff V., Goetz R., Kuro O., Mohammadi M., et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007, 117:4003-4008.
15. Krajisnik T., Bjorklund P., Marsell R., Ljunggren O., Akerstrom G., Jonsson K.B., et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007, 195:125-131.
16. Silver J., Naveh-Many T., Mayer H., Schmelzer H.J., Popovtzer M.M. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in vivo in the rat. J Clin Invest 1986, 78:1296-1301.
17. Silver J., Russell J., Sherwood L.M. Regulation by vitamin D metabolites of messenger ribonucleic acid for preproparathyroid hormone in isolated bovine parathyroid cells. Proc Natl Acad Sci U S A 1985, 82:4270-4273.
18. Coburn J.W., Koppel M.H., Brickman A.S., Massry S.G. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973, 3:264-272.
19. Holick M.F. Vitamin D and the kidney. Kidney Int 1987, 32:912-929.
20. Clemens T.L., Adams J.S., Henderson S.L., Holick M.F. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. Lancet 1982, 1:74-76.
21. Ritter C.S., Armbrecht H.J., Slatopolsky E., Brown A.J. 25-Hydroxyvitamin D(3) suppresses PTH synthesis and secretion by bovine parathyroid cells. Kidney Int 2006, 70:654-659.
22. Zisman A.L., Hristova M., Ho L.T., Sprague S.M. Impact of ergocalciferol treatment of vitamin D deficiency on serum parathyroid hormone concentrations in chronic kidney disease. Am J Nephrol 2007, 27:36-43.
23. Chandra P., Binongo J.N., Ziegler T.R., Schlanger L.E., Wang W., Someren J.T., et al. Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study. Endocr Pract 2008, 14:10-17.
24. Shroff R., Wan M., Rees L. Can vitamin D slow down the progression of chronic kidney disease?. Pediatr Nephrol 2012, 27:2167-2173.
25. Slatopolsky E., Caglar S., Pennell J.P., Taggart D.D., Canterbury J.M., Reiss E., et al. On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog. J Clin Invest 1971, 50:492-499.
26. Llach F., Massry S.G. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab 1985, 61:601-606.
27. Almaden Y., Canalejo A., Ballesteros E., Anon G., Canadillas S., Rodriguez M. Regulation of arachidonic acid production by intracellular calcium in parathyroid cells: effect of extracellular phosphate. J Am Soc Nephrol 2002, 13:693-698.
28. Silver J., Kilav R., Sela-Brown A., Naveh-Many T. Molecular mechanisms of secondary hyperparathyroidism. Pediatr Nephrol 2000, 14:626-628.
29. Brown E.M., Gamba G., Riccardi D., Lombardi M., Butters R., Kifor O., et al. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Nature 1993, 366:575-580.
30. John M.R., Goodman W.G., Gao P., Cantor T.L., Salusky I.B., Juppner H. A novel immunoradiometric assay detects full-length human PTH but not amino-terminally truncated fragments: implications for PTH measurements in renal failure. J Clin Endocrinol Metab 1999, 84:4287-4290.
31. Freichel M., Zink-Lorenz A., Holloschi A., Hafner M., Flockerzi V., Raue F. Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion. Endocrinology 1996, 137:3842-3848.
32. Kirkwood J.R., Ozonoff M.B., Steinbach H.L. Epiphyseal displacement after metaphyseal fracture in renal osteodystrophy. Am J Roentgenol Radium Ther Nucl Med 1972, 115:547-554.
33. Martin-Salvago M., Villar-Rodriguez J.L., Palma-Alvarez A., Beato-Moreno A., Galera-Davidson H. Decreased expression of calcium receptor in parathyroid tissue in patients with hyperparathyroidism secondary to chronic renal failure. Endocr Pathol 2003, 14:61-70.
34. Canaff L., Hendy G.N. Human calcium-sensing receptor gene. Vitamin D response elements in promoters P1 and P2 confer transcriptional responsiveness to 1,25-dihydroxyvitamin D. J Biol Chem 2002, 277:30337-30350.
35. Li Y.C., Pirro A.E., Amling M., Delling G., Baron R., Bronson R., et al. Targeted ablation of the vitamin D receptor: an animal model of vitamin D-dependent rickets type II with alopecia. Proc Natl Acad Sci U S A 1997, 94:9831-9835.
36. Brown A.J., Zhong M., Ritter C., Brown E.M., Slatopolsky E. Loss of calcium responsiveness in cultured bovine parathyroid cells is associated with decreased calcium receptor expression. Biochem Biophys Res Commun 1995, 212:861-867.
37. Wada M., Furuya Y., Sakiyama J., Kobayashi N., Miyata S., Ishii H., et al. The calcimimetic compound NPS R-568 suppresses parathyroid cell proliferation in rats with renal insufficiency. Control of parathyroid cell growth via a calcium receptor. J Clin Invest 1997, 100:2977-2983.
38. K/DOQI clinical practice guidelines for bone metabolism and disease in children with chronic kidney disease. Am J Kidney Dis 2005, 46:S1-S121. National Kidney Foundation.
39. Salusky I.B., Coburn J.W., Brill J., Foley J., Slatopolsky E., Fine R.N., et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 1988, 33:975-982.
40. Atkins D., Peacock M. A comparison of the effects of the calcitonins, steroid hormones and thyroid hormones on the response of bone to parathyroid hormone in tissue culture. J Endocrinol 1975, 64:573-583.
41. Lee K., Deeds J.D., Bond A.T., Juppner H., bou-Samra A.B., Segre G.V. In situ localization of PTH/PTHrP receptor mRNA in the bone of fetal and young rats. Bone 1993, 14:341-345.
42. Sabbagh Y., Graciolli F.G., O'Brien S., Tang W., Dos Reis L.M., Ryan S., et al. Repression of osteocyte Wnt/beta-catenin signaling is an early event in the progression of renal osteodystrophy. J Bone Miner Res 2012, 27:1757-1772.
43. Malluche H., Faugere M.C. Renal bone disease 1990: an unmet challenge for the nephrologist. Kidney Int 1990, 38:193-211.
44. Cejka D., Herberth J., Branscum A.J., Fardo D.W., Monier-Faugere M.C., Diarra D., et al. Sclerostin and Dickkopf-1 in renal osteodystrophy. Clin J Am Soc Nephrol 2011, 6:877-882.
45. Wesseling-Perry K., Pereira R.C., Tseng C.H., Elashoff R., Zaritsky J.J., Yadin O., et al. Early skeletal and biochemical alterations in pediatric chronic kidney disease. Clin J Am Soc Nephrol 2012, 7:146-152.
46. Groothoff J.W., Offringa M., Van Eck-Smit B.L., Gruppen M.P., Van De Kar N.J., Wolff E.D., et al. Severe bone disease and low bone mineral density after juvenile renal failure. Kidney Int 2003, 63:266-275.
47. Hamdy N.A., Kanis J.A., Beneton M.N., Brown C.B., Juttmann J.R., Jordans J.G., et al. Effect of alfacalcidol on natural course of renal bone disease in mild to moderate renal failure. BMJ 1995, 310:358-363.
48. Lobao R., Carvalho A.B., Cuppari L., Ventura R., Lazaretti-Castro M., Jorgetti V., et al. High prevalence of low bone mineral density in pre-dialysis chronic kidney disease patients: bone histomorphometric analysis. Clin Nephrol 2004, 62:432-439.
49. Goodman W.G., Ramirez J.A., Belin T.R., Chon Y., Gales B., Segre G.V., et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 1994, 46:1160-1166.
50. Salusky I.B., Coburn J.W., Foley J., Nelson P., Fine R.N. Effects of oral calcium carbonate on control of serum phosphorus and changes in plasma aluminum levels after discontinuation of aluminum-containing gels in children receiving dialysis. J Pediatr 1986, 108:767-770.
51. Sherrard D.J. Renal osteodystrophy. Semin Nephrol 1986, 6:56-67.
52. Ott S.M., Maloney N.A., Klein G.L., Alfrey A.C., Ament M.E., Coburn J.W., et al. Aluminum is associated with low bone formation in patients receiving chronic parenteral nutrition. Ann Intern Med 1983, 98:910-914.
53. London G.M., Marty C., Marchais S.J., Guerin A.P., Metivier F., de Vernejoul M.C. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol 2004, 15:1943-1951.
54. Kuizon B.D., Goodman W.G., Juppner H., Boechat I., Nelson P., Gales B., et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 1998, 53:205-211.
55. Kuizon B.D., Salusky I.B. Intermittent calcitriol therapy and growth in children with chronic renal failure. Miner Electrolyte Metab 1998, 24:290-295.
56. Wesseling-Perry K., Pereira R.C., Sahney S., Gales B., Wang H.J., Elashoff R., et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011, 79:112-119.
57. Salusky I.B., Ramirez J.A., Oppenheim W., Gales B., Segre G.V., Goodman W.G. Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 1994, 45:253-258.
58. Munns C.F., Rauch F., Travers R., Glorieux F.H. Three children with lower limb fractures and a mineralization defect: a novel bone fragility disorder?. Bone 2004, 35:1023-1028.
59. Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 2000, 26:345-348. ADHR Consortium.
60. Wesseling-Perry K., Pereira R.C., Sahney S., Gales B., Wang H.J., Elashoff R., et al. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism. Kidney Int 2011, 79:112-119.
61. Salusky I.B., Goodman W.G., Kuizon B.D., Lavigne J.R., Zahranik R.J., Gales B., et al. Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003, 63:1801-1808.
62. Salusky I.B., Goodman W.G., Sahney S., Gales B., Perilloux A., Wang H.J., et al. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols. J Am Soc Nephrol 2005, 16:2501-2508.
63. Ho A.Y., Kung A.W. Determinants of peak bone mineral density and bone area in young women. J Bone Miner Metab 2005, 23:470-475.
64. Mahesh S., Kaskel F. Growth hormone axis in chronic kidney disease. Pediatr Nephrol 2008, 23:41-48.
65. Guyton A., Hall J. Pituitary hormones and their control by the hypothalamus. Textbook of medical physiology 2006, 918-929. Elsevier Saunders, Philadelphia. A. Guyton (Ed.).
66. Tonshoff B., Schaefer F., Mehls O. Disturbance of growth hormone-insulin-like growth factor axis in uraemia. Implications for recombinant human growth hormone treatment. Pediatr Nephrol 1990, 4:654-662.
67. Rees L., Azocar M., Borzych D., Watson A.R., Buscher A., Edefonti A., et al. Growth in very young children undergoing chronic peritoneal dialysis. J Am Soc Nephrol 2011, 22:2303-2312.
68. 2008 Annual Report 2008, North American Pediatric Renal Transplant Cooperative Study (NAPRTCS).
69. Waller S.C., Ridout D., Cantor T., Rees L. Parathyroid hormone and growth in children with chronic renal failure. Kidney Int 2005, 67:2338-2345.
70. Schmitt C.P., Ardissino G., Testa S., Claris-Appiani A., Mehls O. Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 2003, 18:440-444.
71. Borzych D., Rees L., Ha I.S., Chua A., Valles P.G., Lipka M., et al. The bone and mineral disorder of children undergoing chronic peritoneal dialysis. Kidney Int 2010, 78:1295-1304.
72. Tonshoff B., Cronin M.J., Reichert M., Haffner D., Wingen A.M., Blum W.F., et al. Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. The European Study Group for Nutritional Treatment of Chronic Renal Failure in Childhood. The German Study Group for Growth Hormone Treatment in Chronic Renal Failure. J Clin Endocrinol Metab 1997, 82:1007-1013.
73. Tonshoff B., Blum W.F., Mehls O. Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int Suppl 1997, 58:S106-S113.
74. Powell D.R., Durham S.K., Liu F., Baker B.K., Lee P.D., Watkins S.L., et al. The insulin-like growth factor axis and growth in children with chronic renal failure: a report of the Southwest Pediatric Nephrology Study Group. J Clin Endocrinol Metab 1998, 83:1654-1661.
75. Milliner D.S., Zinsmeister A.R., Lieberman E., Landing B. Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 1990, 38:931-936.
76. Goodman W.G., Goldin J., Kuizon B.D., Yoon C., Gales B., Sider D., et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000, 342:1478-1483.
77. Oh J., Wunsch R., Turzer M., Bahner M., Raggi P., Querfeld U., et al. Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 2002, 106:100-105.
78. Litwin M., Wuhl E., Jourdan C., Trelewicz J., Niemirska A., Fahr K., et al. Altered morphologic properties of large arteries in children with chronic renal failure and after renal transplantation. J Am Soc Nephrol 2005, 16:1494-1500.
79. Chavers B.M., Li S., Collins A.J., Herzog C.A. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int 2002, 62:648-653.
80. Shroff R.C., McNair R., Figg N., Skepper J.N., Schurgers L., Gupta A., et al. Dialysis accelerates medial vascular calcification in part by triggering smooth muscle cell apoptosis. Circulation 2008, 118:1748-1757.
81. Shroff R.C., McNair R., Skepper J.N., Figg N., Schurgers L.J., Deanfield J., et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol 2010, 21:103-112.
82. Russo D., Palmiero G., De Blasio A.P., Balletta M.M., Andreucci V.E. Coronary artery calcification in patients with CRF not undergoing dialysis. Am J Kidney Dis 2003, 44:1024-1030.
83. Ducy P., Zhang R., Geoffroy V., Ridall A.L., Karsenty G. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell 1997, 89:747-754.
84. Moe S.M., Duan D., Doehle B.P., O'Neill K.D., Chen N.X. Uremia induces the osteoblast differentiation factor Cbfa1 in human blood vessels. Kidney Int 2003, 63:1003-1011.
85. Jono S., McKee M.D., Murry C.E., Shioi A., Nishizawa Y., Mori K., et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ Res 2000, 87:E10-E17.
86. Ahmed S., O'Neill K.D., Hood A.F., Evan A.P., Moe S.M. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis 2001, 37:1267-1276.
87. Bostrom K. Insights into the mechanism of vascular calcification. Am J Cardiol 2001, 88:20E-22E.
88. Moe S.M., O'Neill K.D., Duan D., Ahmed S., Chen N.X., Leapman S.B., et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 2002, 61:638-647.
89. Chen N.X., O'Neill K.D., Duan D., Moe S.M. Phosphorus and uremic serum up-regulate osteopontin expression in vascular smooth muscle cells. Kidney Int 2002, 62:1724-1731.
90. Schinke T., Amendt C., Trindl A., Poschke O., Muller-Esterl W., Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem 1996, 271:20789-20796.
91. Sweatt A., Sane D.C., Hutson S.M., Wallin R. Matrix Gla protein (MGP) and bone morphogenetic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003, 1:178-185.
92. Schafer C., Heiss A., Schwarz A., Westenfeld R., Ketteler M., Floege J., et al. The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest 2003, 112:357-366.
93. Hu M.C., Shi M., Zhang J., Quinones H., Griffith C., Kuro-o M., et al. Klotho deficiency causes vascular calcification in chronic kidney disease. J Am Soc Nephrol 2011, 22:124-136.
94. Lim K., Lu T.S., Molostvov G., Lee C., Lam F., Zehnder D., et al. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to FGF-23. Circulation 2012, 125:2243-2255.
95. Jean G., Bresson E., Terrat J.C., Vanel T., Hurot J.M., Lorriaux C., et al. Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant 2009, 24:948-955.
96. Srivaths P.R., Goldstein S.L., Silverstein D.M., Krishnamurthy R., Brewer E.D. Elevated FGF 23 and phosphorus are associated with coronary calcification in hemodialysis patients. Pediatr Nephrol 2011, 26:945-951.
97. Tom A., McCauley L., Bell L., Rodd C., Espinosa P., Yu G., et al. Growth during maintenance hemodialysis: impact of enhanced nutrition and clearance. J Pediatr 1999, 134:464-471.
98. Fischbach M., Terzic J., Menouer S., Dheu C., Soskin S., Helmstetter A., et al. Intensified and daily hemodialysis in children might improve statural growth. Pediatr Nephrol 2006, 21:1746-1752.
99. Hothi D.K., Harvey E., Piva E., Keating L., Secker D., Geary D.F. Calcium and phosphate balance in adolescents on home nocturnal haemodialysis. Pediatr Nephrol 2006, 21:835-841.
100. Block G.A., Spiegel D.M., Ehrlich J., Mehta R., Lindbergh J., Dreisbach A., et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005, 68:1815-1824.
101. Block G.A., Raggi P., Bellasi A., Kooienga L., Spiegel D.M. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007, 71:438-441.
102. Di Iorio B., Bellasi A., Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012, 7:487-493.
103. Mahdavi H., Kuizon B.D., Gales B., Wang H.J., Elashoff R.M., Salusky I.B. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children. Pediatr Nephrol 2003, 18:1260-1264.
104. D'Haese P.C., Spasovski G.B., Sikole A., Hutchison A., Freemont T.J., Sulkova S., et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003, 85:S73-S78.
105. Hutchison A.J., Speake M., Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004, 19:1902-1906.
106. Finn W.F., Joy M.S., Hladik G. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodialysis. Clin Nephrol 2004, 62:193-201.
107. Spasovski G.B., Sikole A., Gelev S., Masin-Spasovska J., Freemont T., Webster I., et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol Dial Transplant 2006, 21:2217-2224.
108. Slatopolsky E., Liapis H., Finch J. Progressive accumulation of lanthanum in the liver of normal and uremic rats. Kidney Int 2005, 68:2809-2813.
109. Isakova T., Wahl P., Vargas G.S., Gutierrez O.M., Scialla J., Xie H., et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011, 79:1370-1378.
110. Lavi-Moshayoff V., Wasserman G., Meir T., Silver J., Naveh-Many T. PTH increases FGF23 gene expression and mediates the high-FGF23 levels of experimental kidney failure: a bone parathyroid feedback loop. Am J Physiol Renal Physiol 2010, 299:F882-F889.
111. Oliveira R.B., Cancela A.L., Graciolli F.G., dos Reis L.M., Draibe S.A., Cuppari L., et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?. Clin J Am Soc Nephrol 2010, 5:286-291.
112. Isakova T., Gutierrez O.M., Smith K., Epstein M., Keating L.K., Juppner H., et al. Pilot study of dietary phosphorus restriction and phosphorus binders to target fibroblast growth factor 23 in patients with chronic kidney disease. Nephrol Dial Transplant 2011, 26:584-591.
113. Gonzalez-Parra E., Gonzalez-Casaus M.L., Galan A., Martinez-Calero A., Navas V., Rodriguez M., et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease stage 3 patients. Nephrol Dial Transplant 2011, 26:2567-2571.
114. Faul C., Amaral A.P., Oskouei B., Hu M.C., Sloan A., Isakova T., et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121:4393-4408.
115. Gutierrez O.M., Januzzi J.L., Isakova T., Laliberte K., Smith K., Collerone G., et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009, 119:2545-2552.
116. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol 2007, 18:2600-2608.
117. Wolf M., Molnar M.Z., Amaral A.P., Czira M.E., Rudas A., Ujszaszi A., et al. Elevated fibroblast growth factor 23 is a risk factor for kidney transplant loss and mortality. J Am Soc Nephrol 2011, 22:956-966.
118. Gutierrez O.M., Mannstadt M., Isakova T., Rauh-Hain J.A., Tamez H., Shah A., et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008, 359:584-592.
119. Bacchetta J., Cochat P., Salusky I.B., Wesseling-Perry K. Uric acid and IGF1 as possible determinants of FGF23 metabolism in children with normal renal function. Pediatr Nephrol 2012, 27:1131-1138.
120. Shroff R., Wan M., Gullett A., Ledermann S., Shute R., Knott C., et al. Ergocalciferol supplementation in children with CKD delays the onset of secondary hyperparathyroidism: a randomized trial. Clin J Am Soc Nephrol 2012, 7:216-223.
121. Waller S., Ledermann S., Trompeter R., van't H.W., Ridout D., Rees L. Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 2003, 18:1236-1241.
122. Coburn J.W., Maung H.M., Elangovan L., Germain M.J., Lindberg J.S., Sprague S.M., et al. Doxercalciferol safely suppresses PTH levels in patients with secondary hyperparathyroidism associated with chronic kidney disease stages 3 and 4. Am J Kidney Dis 2004, 43:877-890.
123. Wada M., Nagano N. Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant 2003, 18(Suppl 3). iii13-7.
124. Martin K.J., Juppner H., Sherrard D.J., Goodman W.G., Kaplan M.R., Nassar G., et al. First- and second-generation immunometric PTH assays during treatment of hyperparathyroidism with cinacalcet HCl. Kidney Int 2005, 68:1236-1243.
125. Serra A.L., Schwarz A.A., Wick F.H., Marti H.P., Wuthrich R.P. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism. Nephrol Dial Transplant 2005, 20:1315-1319.
126. Chang W., Tu C., Bajra R., Komuves L., Miller S., Strewler G., et al. Calcium sensing in cultured chondrogenic RCJ3.1C5.18 cells. Endocrinology 1999, 140:1911-1919.
127. Gardner J., Ashraf A., You Z., McCormick K. Changes in plasma FGF23 in growth hormone deficient children during rhGH therapy. J Pediatr Endocrinol Metab 2011, 24:645-650.
128. Fine R.N., Kohaut E.C., Brown D., Perlman A.J. Growth after recombinant human growth hormone treatment in children with chronic renal failure: report of a multicenter randomized double-blind placebo-controlled study. Genentech Cooperative Study Group. J Pediatr 1994, 124:374-382.
129. Schaefer F., Wuhl E., Haffner D., Mehls O. Stimulation of growth by recombinant human growth hormone in children undergoing peritoneal or hemodialysis treatment. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. Adv Perit Dial 1994, 10:321-326.
130. Mitsnefes M.M., Kimball T.R., Kartal J., Witt S.A., Glascock B.J., Khoury P.R., et al. Cardiac and vascular adaptation in pediatric patients with chronic kidney disease: role of calcium-phosphorus metabolism. J Am Soc Nephrol 2005, 16:2796-2803.
131. Tonelli M., Keech A., Shepherd J., Sacks F., Tonkin A., Packard C., et al. Effect of pravastatin in people with diabetes and chronic kidney disease. J Am Soc Nephrol 2005, 16:3748-3754.
132. Holdaas H., Fellstrom B., Cole E., Nyberg G., Olsson A.G., Pedersen T.R., et al. Long-term cardiac outcomes in renal transplant recipients receiving fluvastatin: the ALERT extension study. Am J Transplant 2005, 5:2929-2936.
133. Wanner C., Krane V., Marz W., Olschewski M., Mann J.F., Ruf G., et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 2005, 353:238-248.